Inhalon Biopharma and Celltrion to partner on inhaled form of regdanvimab for treatment of COVID-19

Jul 22, 2021

Inhalon Biopharma announced it will partner with Celltrion to develop IN-006, an inhaled form of regdanvimab for the treatment of COVID-19. It is hoped that the product will be able to reach the virus in the airways and allow patients to self-administer treatment at home. Last week we reported that regdanvimab demonstrated strong neutralising activity against the Delta variant of COVID-19 in pre-clinical studies.

Print Page Mail Article